Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with metastatic non-small cell lung cancer (NSCLC).

Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with anti-PD-(L)1 refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC).

Report on treatment advances in advanced solid tumors presented at ESMO 2021.

Report on updates in the treatment of lung cancer presented at WCLC and ESMO 2021.

Report on updates in the treatment of lung and gastrointestinal cancers presented at ESMO 2021.